Pulmonary hypertension owing to lung disease and/or hypoxia

Summary

Pulmonary hypertension owing to lung disease and/or hypoxia (MONDO:0017157) is a disease. A subtype of pulmonary hypertension — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pulmonary hypertension owing to lung disease and/or hypoxia
Mondo ID	MONDO:0017157
Orphanet	275837
SNOMED CT	697910001
UMLS	C3698136
MedGen	785400
GARD	0021034
Is cancer (heuristic)	no

Also known as: PH due to lung disease and/or hypoxia · PH owing to lung disease and/or hypoxia · pulmonary hypertension due to lung disease and/or hypoxia

Disease family

This is a subtype of pulmonary hypertension. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › hypertensive disorder › pulmonary hypertension › pulmonary hypertension owing to lung disease and/or hypoxia

Related subtypes (5): Braddock syndrome, chronic thromboembolic pulmonary hypertension, hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome, pulmonary arterial hypertension, pulmonary hypertension, neonatal

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.